Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.

Part of the Blood Cancer United Dare to Dream Project, the collaboration serves a dual purpose: empowering patients with their health-related data and information relevant to their journey and fueling broader scientific breakthroughs.